FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W619239484> ?p ?o ?g. }

• W619239484 endingPage "20662" @default.
• W619239484 startingPage "20662" @default.
• W619239484 abstract "20662 Background: The efficacy and toxicity of Pemetrexed (P) in Asian patients is unknown. Methods: Retrospective review of patients treated with P in a single institution between July 2005 and November 2007. Medical records, radiologic and laboratory data were reviewed. RECIST were used to assess efficacy independently of the treating physician’s assessment. National Cancer Institute CTCAE v3.0 were used for the description of adverse events. Results: Forty-three patients received P: 37 had NSCLC and 6 had mesothelioma. Patients with NSCLC had a median age of 60 years (range, 45 to 89), and were predominantly male (29 men and 8 women), ethnic Chinese (32 patients) and smokers (22 patients). Histology was as follows: NSCLC, 19; adenocarcinoma, 12; squamous cell carcinoma, 4; bronchioalveolar and large cell, 1 each. Twenty-four patients had stage IV at diagnosis, 12 had stage III and 1 had stage II. All had received at least one prior regimen (median 1, range 1 to 4): Carboplatin and Gemcitabine, 21 patients; Carboplatin, Irinotecan and Paclitaxel, 9; Gefitinib, 9; Carboplatin and Paclitaxel, 6; Erlotinib, 2; Gemcitabine and Cisplatin, Single agent paclitaxel, Carboplatin and Docetaxel, Cisplatin and Etoposide, 1 patient each. Twenty-nine individuals had an ECOG PS of 0 or 1. Patients received a median of 2 cycles (total, 95; range 1 to 12). Grade 3 and 4 adverse events were as follows: anemia, 3 patients; pneumonia, 2 patients; neutropenic fever, 1 patient; thrombocytopenia, 1 patient. Five (14%) patients had an objective response (1 CR, 4 PR) and 13 (35%) had stable disease. Median Time to Treatment Failure was 8 weeks. Median overall survival was 80 weeks. The median age for patients with mesothelioma was 46.5 years (range 29 to 73). Five men and one woman (4 ethnic Chinese, 1 Indian and 1 Arab) received a median of 4 cycles (total 30, range 1 to 15) of Pemetrexed in combination with cisplatin. Three patients had a PR, 2 had SD and one had progressed at the time of first evaluation. Grade 3 and 4 toxicity was as follows: leukocytopenia, neutropenia, and thrombocytopenia, 1 patient. Conclusions: Pemetrexed is safe and active in the treatment of Asian patients with NSCLC and mesothelioma. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Eli Lilly" @default.
• W619239484 created "2016-06-24" @default.
• W619239484 creator A5030134943 @default.
• W619239484 creator A5042232313 @default.
• W619239484 creator A5046825078 @default.
• W619239484 creator A5047834574 @default.
• W619239484 creator A5068401391 @default.
• W619239484 creator A5070509518 @default.
• W619239484 creator A5084222109 @default.
• W619239484 date "2008-05-20" @default.
• W619239484 modified "2023-09-26" @default.
• W619239484 title "Pemetrexed in the treatment of Asian patients with non-small cell lung cancer (NSCLC) and mesothelioma: Experience at the Johns Hopkins Singapore International Medical Centre" @default.
• W619239484 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.20662" @default.
• W619239484 hasPublicationYear "2008" @default.
• W619239484 type Work @default.
• W619239484 sameAs 619239484 @default.
• W619239484 citedByCount "0" @default.
• W619239484 crossrefType "journal-article" @default.
• W619239484 hasAuthorship W619239484A5030134943 @default.
• W619239484 hasAuthorship W619239484A5042232313 @default.
• W619239484 hasAuthorship W619239484A5046825078 @default.
• W619239484 hasAuthorship W619239484A5047834574 @default.
• W619239484 hasAuthorship W619239484A5068401391 @default.
• W619239484 hasAuthorship W619239484A5070509518 @default.
• W619239484 hasAuthorship W619239484A5084222109 @default.
• W619239484 hasConcept C121608353 @default.
• W619239484 hasConcept C126322002 @default.
• W619239484 hasConcept C143998085 @default.
• W619239484 hasConcept C2776256026 @default.
• W619239484 hasConcept C2776694085 @default.
• W619239484 hasConcept C2776907518 @default.
• W619239484 hasConcept C2777240266 @default.
• W619239484 hasConcept C2778239845 @default.
• W619239484 hasConcept C2778336483 @default.
• W619239484 hasConcept C2778822529 @default.
• W619239484 hasConcept C2779438470 @default.
• W619239484 hasConcept C2779984678 @default.
• W619239484 hasConcept C2780258809 @default.
• W619239484 hasConcept C2780259306 @default.
• W619239484 hasConcept C2780580887 @default.
• W619239484 hasConcept C2781190966 @default.
• W619239484 hasConcept C2781413609 @default.
• W619239484 hasConcept C2781451048 @default.
• W619239484 hasConcept C526805850 @default.
• W619239484 hasConcept C71924100 @default.
• W619239484 hasConceptScore W619239484C121608353 @default.
• W619239484 hasConceptScore W619239484C126322002 @default.
• W619239484 hasConceptScore W619239484C143998085 @default.
• W619239484 hasConceptScore W619239484C2776256026 @default.
• W619239484 hasConceptScore W619239484C2776694085 @default.
• W619239484 hasConceptScore W619239484C2776907518 @default.
• W619239484 hasConceptScore W619239484C2777240266 @default.
• W619239484 hasConceptScore W619239484C2778239845 @default.
• W619239484 hasConceptScore W619239484C2778336483 @default.
• W619239484 hasConceptScore W619239484C2778822529 @default.
• W619239484 hasConceptScore W619239484C2779438470 @default.
• W619239484 hasConceptScore W619239484C2779984678 @default.
• W619239484 hasConceptScore W619239484C2780258809 @default.
• W619239484 hasConceptScore W619239484C2780259306 @default.
• W619239484 hasConceptScore W619239484C2780580887 @default.
• W619239484 hasConceptScore W619239484C2781190966 @default.
• W619239484 hasConceptScore W619239484C2781413609 @default.
• W619239484 hasConceptScore W619239484C2781451048 @default.
• W619239484 hasConceptScore W619239484C526805850 @default.
• W619239484 hasConceptScore W619239484C71924100 @default.
• W619239484 hasIssue "15_suppl" @default.
• W619239484 hasLocation W6192394841 @default.
• W619239484 hasOpenAccess W619239484 @default.
• W619239484 hasPrimaryLocation W6192394841 @default.
• W619239484 hasRelatedWork W1967863863 @default.
• W619239484 hasRelatedWork W1975425037 @default.
• W619239484 hasRelatedWork W2005371059 @default.
• W619239484 hasRelatedWork W2013653877 @default.
• W619239484 hasRelatedWork W2031554341 @default.
• W619239484 hasRelatedWork W2049014868 @default.
• W619239484 hasRelatedWork W2123354789 @default.
• W619239484 hasRelatedWork W2222727161 @default.
• W619239484 hasRelatedWork W2471989939 @default.
• W619239484 hasRelatedWork W3127521146 @default.
• W619239484 hasVolume "26" @default.
• W619239484 isParatext "false" @default.
• W619239484 isRetracted "false" @default.
• W619239484 magId "619239484" @default.
• W619239484 workType "article" @default.